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implantation in femur: a case report
Weisong Li1,2, Dan Li3*, Xiansen Zhu1, Shaohui Lu4, Chunlei He5 and Qingchun Yang1*Abstract
Myxofibrosarcoma is a myxoid variant of malignant fibrous histiocytoma that most commonly involves the extremities
of elderly people. However, a primary myxofibrosarcoma with bone invasion in young adults is extremely rare. Herein,
we report the case of a 31-year-old male with a gradually enlarging left thigh mass, who had a history of left femur
fracture and received an open reduction and internal fixation with titanium alloy plates and screws 33 months previously.
Imaging investigations revealed an irregularly shaped soft tissue mass around the left femur shaft and a partial bone
defect in the middle one-third of the left femur. Pathological examination of the resected specimen showed a
multi-nodular appearance, abundant myxoid matrix and elongated curvilinear capillaries. Immunohistochemical
studies revealed that the tumor cells was positive for VIM and MDM2, and was negative for CK, MSA, SMA, DES, S-100
and CD34. Labeling index of Ki-67 was 25%. Based on the morphological finding and immunostaining, it was diagnosed
as a low-grade myxofibrosarcoma. The clinical and imaging examinations did not reveal the evidence of a primary cancer
elsewhere, and the patient had no personal or family history of malignancy. To our knowledge, this is the first case of a
primary myxofibrosarcoma developed following a fracture and metal implantation in young adults.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1745984882113605
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Myxofibrosarcoma is a myxoid variant of malignant fi-
brous histiocytoma (MFH), characterized by a nodular
appearance, prominent myxoid matrix, elongated curvi-
linear capillaries, and location mostly in dermal and sub-
cutaneous tissues in the extremities of elderly people
[1-3]. In 1996, Mentzel et al. [3] reported 75 cases of
myxofibrosarcomas and divided these tumors into low-,
intermediate-, and high-grade categories, depending on
the degree of cytologic atypia and the presence or ab-
sence of pleomorphic MFH-like lesion within the tumor.
Tumors of the low-grade category showed a mainly myx-
oid with mild cytologic atypia, while high-grade tumors
showed a pleomorphic appearance with multinucleated
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stated.Several clinical studies of myxofibrosarcomas showed
that approximately 80% of the tumors occurred in the
extremities and about 12% in the trunk, with a high inci-
dence in the dermal or subcutaneous tissues [1-3]. Other
sites for myxofibrosarcomas included head and neck re-
gion, retroperitoneum, pelvis and heart [3,4]. However, a
primary myxofibrosarcoma with bone invasion was rarely
reported [5-11]. In addition, the peak age incidence of
myxofibrosarcomas was in the fifth to seventh decades
with a slight male predominance [2,12].
Herein, we report a low-grade myxofibrosarcoma with
left femur invasion in a 31-year-old male, and present
the clinical, radiological and histopathological character-
istics of this tumor. The clinical and imaging examina-
tions did not reveal the evidence of a primary cancer
elsewhere, and the patient had no personal or family his-
tory of malignancy. It is noteworthy that the patient had
a history of left femur fracture and received an open re-
duction and internal fixation with titanium alloy plates
and screws 33 months previously. To our knowledge,
this is the first report on a primary myxofibrosarcomahis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ation in young adults.
Case presentation
A 31-year-old male patient has a history of a multiple
fracture involving the left femur shaft, the middle and
distal segment of the left tibiofibula, as a result of a traf-
fic accident in October 2008. Subsequently, the patient
underwent an open reduction and internal fixation (ORIF),
using titanium alloy plates and screws. Ten months after
ORIF, an X-ray examination showed no displacement of
the fracture site, and the bridging callus was visible on two
standard views with partial obliteration of the fracture line.
However, the patient did not undergo reoperation to re-
move the metal implants due to financial difficulties.
In August 2011, the patient complained of a 3-month
history of a gradually enlarging left thigh mass. Physical
examination revealed a 12 × 10 cm firm, tender and fixed
mass in the anteromedial left thigh, with local superficial
venous engorgement and skin temperature increment.
Percussion pain in the axial direction of the left lower
limb was absent. The inguinal lymph nodes were not
palpable. Routine chest radiograph and abdominal ultra-
sound examination showed no abnormalities. Other rou-
tine tests, including plasma biochemistry, liver function
tests and urinalysis, were normal.
The X-ray examination demonstrated an ill-defined
osteolytic lesion with disappearance of the medial cor-
tical bone in the middle of the left femur shaft, as well
as an ambiguous image of a soft tissue mass. Computed
tomography (CT) images clearly showed a partial bone
defect approximately 9.7 cm in length on the medial
border of the left femur shaft. A 9.7 × 11 × 19 cm irregu-
larly shaped soft tissue mass was observed around the
left femur, with the surrounding tissues compressed and
shifted significantly (Figure 1). CT findings also showed
that the soft tissue mass was heterogeneous in density
with CT value of 36 HU, in which small pieces of slightly
high-density lesions were found. These imaging findings
suggested that the mass was neoplastic.
Tissue biopsy was performed, and histopathological
examination reported that the tumor was predominantly
composed of a large number of diffuse fusiform cells
and myxoid matrix. The fusiform tumor cells were
arranged in a multi-nodular pattern, with indistinct
cell margins, slightly eosinophilic cytoplasm, and hyper-
chromatic atypical nuclei. Mitoses were infrequent. In
addition, many elongated curvilinear capillaries were ob-
served (Figure 2). These cytological findings suggested a
malignant tumor of mesenchymal origin.
On 3 September 2011, the patient underwent oper-
ation for the metal implants removal and tumor resec-
tion. Intraoperative findings indicated that the tumor
infiltrated into the middle of the femur shaft and thesurrounding tissues including the rectus femoris, sartorius,
pectineal muscle, long adductor muscle, gracilis muscle,
vastus medialis, vastus lateralis, vastus intermedius, and
biceps femoris. The tumor and bone tumor segment ap-
proximately 15 cm in length were resected, and the surgi-
cal margin was microscopically free of tumor. Sequential
bone defect reconstruction after tumor resection was per-
formed by reimplantation with the alcohol inactivated
bone tumor segment, in which the vascularised autologous
left fibula approximately 18 cm in length was inserted.
Then, an internal fixation with titanium alloy plates and
screws was once again performed, and a closed vacuum
drainage system was used.
Macroscopically, the excised specimen was a grayish-
white or grayish-brown mass measured 7 × 14 × 10 cm.
On the cut section, a fish-like appearance with central
necrosis area was observed. Microscopic features were
identical to that of the biopsy. Immunohistochemical
studies showed that the tumor cells expressed strong
immunoreactivity for vimentin (VIM) and negative for
cytokeratin (CK), suggesting a mesenchymal histogenesis
(Figure 3a and b). Labeling index of Ki-67 (the number
of Ki-67 positive tumor cells divided by the sum of Ki-67
positive and negative tumor cells) was 25% (Figure 3c).
Muscle-specific actin (MSA), smooth muscle actin (SMA)
and desmin (DES) were negative in the tumor cells,
eliminating the possibility of a muscle-derived tumor
(Figure 3d-f) [13]. The negative expression of S-100 pro-
tein eliminated a tumor of neural or adipose tissue origin
(Figure 3g). The tumor cells were negative for cluster of
differentiation 34 (CD34) (Figure 3h), B cell lymphoma/
lewkmia-2 and anaplastic lymphoma kinase, which elimi-
nated the possibility of a solitary fibrous tumor or inflam-
matory myofibroblastic tumor [14]. Interestingly, the
positive staining of CD34 in vascular endothelial cells
highlighted the curvilinear capillaries, which was an
important histological feature of myxofibrosarcoma. In
addition, positive expression of murine double minute 2
(MDM2) was observed in the tumor cells. Although
MDM2 immunostaining is useful adjunct in diagnosing
well-differentiated and dedifferentiated liposarcoma sub-
types, overexpression of MDM2 has also been reported
in a small number of myxofibrosarcomas [15-17]. The
combination of clinical and pathological features revealed
a low-grade myxofibrosarcoma.
The patient received three cycles of postoperative ad-
juvant chemotherapy with a combination of ifosfamide,
doxorubicin, cisplatin and mesna, and he experienced no
special discomfort during chemotherapy. In June 2012,
the patient underwent the third operation for the re-
moval of metal implants due to implant breakage in an
accidental fall, followed by external fixation.
However, in June 2013, only 22 months after tumor re-
section, a firm and painless mass approximately 5 cm in
Figure 2 Histopathological examination of the tumor. (a) Magnification, ×40. (b) Magnification, ×100. H&E staining showed that the tumor was
predominantly composed of a large number of diffuse fusiform cells and myxoid matrix. The fusiform tumor cells were arranged in a multi-nodular
pattern, with indistinct cell margins, slightly eosinophilic cytoplasm, and hyperchromatic atypical nuclei. Mitoses were infrequent. Many elongated
curvilinear capillaries were observed.
Figure 1 CT images of the left thigh. (a) Transverse image. (b) Coronal image. A high-resolution volumetric CT scanning revealed a 9.7 × 11 ×
19 cm irregularly shaped soft tissue mass in the anteromedial left thigh (yellow arrow) and a partial bone defect approximately 9.7 cm in length
on the medial border of the left femur shaft (light blue arrow).
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Figure 3 Immunohistochemical studies of the tumor. (a-i) Magnification, ×200. The tumor cells expressed strong immunoreactivity for VIM
(a) and negative for CK (b). Labeling index of Ki-67 (c) was 25%. MSA (d), SMA (e), DES (f) and S-100 protein (g) were negative in the tumor cells.
(h) CD34 staining was detected in vascular endothelial cells rather than in tumor cells, highlighting the curvilinear capillaries. (i) MDM2 was positive
in the tumor cells.
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resonance imaging (MRI) showed an irregular soft tissue
mass with ill-defined margin in the anteromedial left
thigh, accompanied by surrounding soft tissue swelling
and normal muscle structure disappearance. Addition-
ally, bone destruction in the left femur shaft was also
observed (Figure 4). Tissue biopsy was performed and
histopathological examination showed that the tumor
exhibited the classical histological features of myxofibro-
sarcoma, including a nodular appearance, prominent
myxoid matrix and elongated curvilinear capillaries. The
morphology of the tumor cells varied from small and
bland to enlarged, bizarre, pleomorphic and multinucle-
ated, suggesting increased atypia and pleomorphism com-
pared with those in the primary tumor (Figure 5). The
combination of clinical and pathological features revealed
a recurrent myxofibrosarcoma with higher malignancy.There was no evidence of distant metastasis. The patient
eventually underwent left hip disarticulation due to the
inability to control the tumor progression.
Discussion
Myxofibrosarcoma, also known as a myxoid variant
of MFH, is one of the most common sarcomas in the
extremities of elderly people, characterized by a high
frequency of local recurrence. Distinctive histological
features included the following: a commonly nodular
growth pattern; a myxoid matrix containing elongated,
curvilinear capillaries; and fusiform, round or stellate
tumor cells with indistinct cell margins, slightly eosino-
philic cytoplasm, and hyperchromatic atypical nuclei
[3]. These lesions varied from a hypocellular, mainly
myxoid, and purely spindle-cell appearance (low-grade
neoplasms) to high-grade, pleomorphic (MFH-like) lesions
Figure 4 MRI images of the thigh. (a) Transverse T2-weighted image. (b) Coronal T1-weighted image. MRI images showed an irregular soft
tissue mass with ill-defined margin in the anteromedial left thigh (yellow arrow), accompanied by surrounding soft tissue swelling and normal
muscle structure disappearance. Bone destruction in the left femur shaft was observed (light blue arrow).
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areas of necrosis [3]. The most common sites for this
tumor are the extremities, predominantly subcutaneous.
Primary myxofibrosarcomas with bone invasion were
rarely occurred, with no more than 15 previous cases
worldwide being reported in the literature [5-11]. Five of
these patients developed myxofibrosarcoma in a long
bone of the extremities, with an average age of 53.2 years
(range, 31 to 84). The clinicopathological features of them
were summarized in Table 1.Figure 5 Histopathological examination of the recurrent tumor. (a) M
the tumor cells exhibited increased atypia and pleomorphism compared w
enlarged, bizarre, pleomorphic and multinucleated. Abundant myxoid matrThe etiology of myxofibrosarcoma remains unknown.
It was previously reported that 2 patients developed a
myxofibrosarcoma after radiotherapy [18,19]. In the
current case, the patient developed a low-grade myxofibro-
sarcoma in the left thigh after a multiple fracture and metal
implantation suffered about 3 years ago. The patient was a
farmer with no known history of potential environmental
hazardous substances exposure, and he was an occasional
smoker and did not drink alcohol. Except for receiving
a metal implantation for osteosynthesis, the patient hadagnification, ×200. (b) Magnification, ×400. H&E staining showed that
ith those in the primary tumor, varying from small and bland to
ix and elongated curvilinear capillaries were also observed.
Table 1 Clinicopathological features of the reported cases of myxofibrosarcomas in bone of the extremities
Reference Year Age (y)/
sex
Size Location Histology Immunohistochemistry Follow up (y)
Kapur P et al. [5] 2004 31/M 5 cm in maximum
dimension
Left tibia nodular contour; myxoid stroma;
spindle to stellate cells with mild
cytologic atypia and rare mitoses
VIM (+), MSA (+), SMA (+),
CD68 (−), Mac-387 (−),
factor XIIIa (−), DES (−)
Not reported
Marotta D et al. [6] 2009 84/M 8 × 5 cm Left tibia spindle cells; polygonal epithelioid
cells with pleomorphism and
elevated mitotic index; necrosis
CD34 (−), SMA (−), DES (−),
caldesmon (−), CK (−),
S-100 (−)
2
Romeo S et al. [7] 2012 39/M Not reported Lower limbs spindle cells; myxoid stroma;
elongated curvilinear thin-walled
blood vessels
CK (−), EMA (−), SMA (−),
DES (−), caldesmon (−)
1.8
Romeo S et al. [7] 2012 44/F Not reported Lower limbs spindle cells; myxoid stroma;
elongated curvilinear thin-walled
blood vessels
CK (−), EMA (−), SMA (−),
DES (−), caldesmon (−)
6
Romeo S et al. [7] 2012 68/M Not reported Lower limbs spindle cells; myxoid stroma;
elongated curvilinear thin-walled
blood vessels
CK (−), EMA (−), SMA (−),
DES (−), caldesmon (−)
13
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patient has no clinical or radiological evidence of a
neoplasm elsewhere in the body, excluding the possi-
bility of a secondary lesion.
There were some literatures about the tumors devel-
oped following a bone fracture. URIST [20] reported a
desmoid tumor developed following a simple fracture of
the radius and ulna. Langer et al. [21] reported a case ofTable 2 Patients with tumors at the site of metal implants





McDougall A [23] 1956 12/M Humerus Stainless ste
screws (FeC
Delgado ER [24] 1958 37/M Tibia Eggers’ plat
Dube VE et al. [25] 1972 58/M Tibia Steel plate
Tayton KJ [26] 1980 4/F Femur Sherman pl
McDonald I [27] 1981 31/M Tibia Sherman pl
Penman HG et al. [28] 1984 75/F Hip Cobalt-chro
Bagó-Granell J et al. [29] 1984 75/F Hip Charnley-M
Swann M [30] 1984 63/M Hip McKee-Farr
Weber PC [31] 1986 76/F Knee CoCrMo pro
Hughes AW et al. [32] 1987 14/M Femur Sherman sc
Haag M et al. [33] 1989 69/F Hip Weber-Hug
Ward JJ et al. [35] 1990 65/F Femur Smith-Peter
Khurana JS et al. [36] 1991 25/M Femur Hansen Stre
Gatti GM et al. [37] 1999 37/M Femur Stainless ste
Hinarejos P et al. [38] 2000 28/M Tibia Stainless ste
Adams JE et al. [39] 2003 63/M Hip Titanium an
Albert A et al. [40] 2009 75/F Knee Insall Burste
Palraj B et al. [41] 2010 70/M Tibia Stainless ste
Dorrestijn O et al. [42] 2011 58/M Femur Unreameda 19-year-old man who developed a giant cell tumor in
the distal ulna following a scaphoid fracture. However,
whether pure fracture plays a role in the genesis of pri-
mary bone tumors remains controversial, because of the
lack of direct evidence. In addition, a series of literatures
have been published with emphasis on the potential
carcinogenic effect of metal implants. As early as 1956,
Oppenheimer et al. [22] observed the carcinogenic effectaterial Tumor type Latent
period (y)
el plate (FeCrNi) and
r)
Ewing’s sarcoma 30
e and screws Osteosarcoma 3
and screws Hemangioendothelioma 26
ate (CoCrMo) and screws Ewing’s sarcoma 7
ate (CoCrMo) and screws Histiocytic lymphoma 17
me prosthesis Osteosarcoma 16
üller prosthesis Malignant fibrous histiocytoma 2
ar prosthesis (CoCrMo) Malignant fibrous histiocytoma 3
sthesis Epitheliod sarcoma 4.5
rew (CoCr) Malignant fibrous histiocytoma 29
gler prosthesis Malignant fibrous histiocytoma 14
sen nail Osteosarcoma 9
et intramedullary nail Malignant fibrous histiocytoma 14
el implant Rhabdomyosarcoma 11
el plate and screws Fibrosarcoma 30
d cobalt alloy prosthesis Osteosarcoma 3
in prosthesis Angiosarcoma 10
el plate and screws Anaplastic large T-cell lymphoma 7
intramedullary nail Osteosarcoma 2
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neously embedding metal foils in rats. Clinical studies on
the carcinogenicity of metal orthopedic implants showed
that a similar tumor category, predominantly sarcomas, de-
veloped at the implant site and the latent periods for tumor
development ranged from 2 years to more than 30 years
[23-42]. The detailed information of these cases was listed
in Table 2. There was no specific association between
tumor type and metal material. In this case, the metal
implants were made of titanium alloy. Adams et al. [39] re-
ported a case of a high-grade osteosarcoma occurring at
the site of a modular porous-surfaced titanium and cobalt
alloy total hip prosthesis 3 years after device implantation.
Nuevo-Ordóñez et al. [43] detected an increased titanium
concentration in the serum of patients with different types
of titanium implants. Although the local and systemic
long-term effects of titanium particles on the human or-
ganism were unknown, their toxic effects were revealed in
cell cultures [44]. This study showed that the particulate
debris from a titanium metal prosthesis induced genomic
instability, mainly consisting of chromatid breaks and re-
productive failure, in primary human fibroblast cells. These
delayed effects were similar to those caused by heavy
metals cadmium and nickel [44].
Case reports of malignant tumors at the site of metal
implants in humans and domestic animals have implicated
carcinogenesis as a potential, although rare, complication
of metal orthopedic implants. The actual incidence of
tumors in association with metal implants cannot be reli-
ably estimated, considering that clinicians and veteri-
narians are not obliged to report adverse reactions to
implants. Although the possibility that the apparent asso-
ciation is coincidental cannot be excluded, orthopedic
surgeons should be aware of the potential carcinogenic
risk of metal implants.
Conclusion
In summary, we described a case of low-grade myxofi-
brosarcoma with bone invasion, which developed follow-
ing a fracture and metal implantation in a young adult.
To our knowledge, this case is the first report of primary
myxofibrosarcoma in association with titanium alloy im-
plants, which should alert doctors to the possible car-
cinogenic risk of titanium alloy implants.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.
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